Perspectivas y utilidad de los biomarcadores inflamatorios en el contexto de la enfermedad renal crónica

Nefrologia

Volumn 27, Issue SUPPL.6, 2007, Pages 8-14

  Navarro, Juan F ^a   Mora, C ^a  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

BLOOD; CHRONIC DISEASE; HUMAN; IMMUNOLOGY; INFLAMMATION; KIDNEY DISEASE; REVIEW;

BIOLOGICAL MARKERS; CHRONIC DISEASE; HUMANS; INFLAMMATION; KIDNEY DISEASES;

EID: 45949104820     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (105)

1. Ross R. Mechanisms of disease: atherosclerosis an inflammatory disease. N Engl J Med 340: 15-26, 1999.
2. Schmidt MI, Duncan BB, Sharrett AR y cols.: Markers of in.ammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 353: 1649-1652, 1999.
3. Pradhan AD, Manson JE, Rifai N y cols.: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286: 327-334, 2001.
4. Festa A, D'Agostino R, Tracey RP, Haffner SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 51: 1131-1137, 2002.
5. Spranger J, Kroke A, Möhlig M, y cols.: In.ammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC) Potsdam study. Diabetes 52: 812-817, 2003.
6. Festa A, D'Agostino R, Howard G y cols.: Chronic subclinical in.ammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 101: 42-47, 2000.
7. Ford ES: Body mass index, diabetes, and C-reactive protein among US adults. Diabetes 22: 1971-1977, 1999.
8. Müller S, Martin S, Koenig W y cols.: Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 45: 805-812, 2002.
9. Temelkova-Kurktschiev T, Henkel E, Koelher C, y cols.: Subclinical in.ammation in newly detected type II diabetes and impaired glucose tolerance. Diabetologia 45: 151, 2002.
10. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J: The prevalence of non-traditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 140: 9-17, 2004.
11. Stenvinkel P, Heimburger O, Paultre F y cols. Strong associations between malnutrition, inflammation and atherosclerosis in chronic renal failure. Kidney Int 55: 1899-1911, 1999.
12. Boltom CH, Downs LG, Victory JGG, Dwight JF, Tomson CRV, Mackness MI y cols.: Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant 16: 1189-97, 2001.
13. Panichi V, Migliori M, De Pietro S, Taccola D, Bianchi AM, Norpoth M, y cols.: C-reactive protein in patients with chronic renal diseases. Renal Fail 23: 551-62, 2001.
14. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA y cols.: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 65: 1009-1016, 2004.
15. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP y cols.: elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107: 87-92, 2003.
16. Stuveling EM, Hillege HL, Bakker SJ, Gans RO, De Jong PE, De Zeeuw D. C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int 63: 654-61, 2003.
17. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB: Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 137: 555-562, 2002.
18. Anavekar NS, McMurray JJV, Velázquez EJ, y cols: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351: 1285-1295, 2004.
19. Ruilope LM, Salvetti A, Jamerson K y cols.: Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) Study. J Am Soc Nephrol 12: 218-225, 2001.
20. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 134: 629-636, 2001.
21. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-Y: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004.
22. Excell L, McDonald S: Deaths, in Excell L, McDonald S (eds): ANZDATA Registry Report 2004. Adelaide, South Aus-tralia, Australia and New Zealand Dialysis and Transplant Registry, 2004, pp. 15-24.
23. Sarnak MJ, Coronado BE, Greene T, y cols.: Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 57: 327-335, 2002.
24. Longenecker JC, Coresh J, Powe NR y cols.: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study. J Am Soc Nephrol 13: 1918-1927, 2002.
25. Cheung AK, Sarnak MJ, Yan G y cols.: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58: 353-362, 2000.
26. Zocalli C, Mallamci F, Tripepi G: Inflammatory proteins as predictors of cardiovascular disease in patients with endstage renal disease. Nephrol Dial Transplant 19(Supl. 5): 67-72, 2004.
27. Roberts MA, Hare DL, Ratnaike S, Ierino FL: Cardiovascular biomarkers in CKD: Pathophysiology and implications for clinical management of cardiac disease. Am J Kidney Dis 48: 341-360, 2006.
28. Libby P: Inflammation in atherosclerosis. Nature 420: 868-874, 2002.
29. Landray MJ, Wheeler DC, Lip GY, y cols: Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: The Chronic Renal Impairment in Birmingham (CRIB) Study. Am J Kidney Dis 3: 244-253, 2004.
30. Knight EL, Rimm EB, Pai JK, y cols: Kidney dysfunction, inflammation, and coronary events: Aprospective study. J Am Soc Nephrol 15: 1897-1903, 2004.
31. Papagianni A, Kalovoulos M, Kirmizis D, y cols: Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic haemodialysis patients. Nephrol Dial Transplant 18: 113-119, 2003.
32. Stenvinkel P, Lindholm B, Heimburger M, Heimburger O: Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: Association with malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Transplant 15: 1624-1630, 2000.
33. Jialal I, Devaraj S, Venugopal SK: C-Reactive protein: Risk marker or mediator in atherothrombosis? Hypertension 44: 6-11, 2004.
34. Arici M, Walls J: End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int 59: 407-414, 2001.
35. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55: 648-658, 1999.
36. Menon V, Greene T, Wang X, y cols: C-Reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 68: 766-772, 2005.
37. Ducloux D, Bresson-Vautrin C, Kribs M, Abdelfatah A, Chalopin JM: C-Reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int 62: 1417-1422, 2002.
38. Iseki K, Tozawa M, Yoshi S, Fukiyama K: Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 14: 1956-1960, 1999.
39. Yeun JY, Levine RA, Mantadilok V, Kaysen GA: C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35: 469-476, 2000.
40. Soriano S, González L, Martín-Malo A, Rodríguez M, Aljama P: C-reactive protein and low albumin are predictors of morbidity and cardiovascular events in chronic kidney disease (CKD) 3-5 patients. Clin Nephrol 67: 353-357, 2007.
41. Korevaar JC, van Manen JG, Dekker FW, de Waart DR, Boeschoten EW, Krediet RT, for the NECOSAD Study Group: Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol 15: 2916-2922, 2004.
42. Vernaglione L, Cristofano C, Muscogiuri P, Chimienti S: Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am J Kidney Dis 43: 471-478, 2004.
43. Ikejiri A, Hirano T, Murayama S y cols.: Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients. Metabolism 53: 1113-1117, 2004.
44. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB: Effects of simvastatin on high-sensitivity C reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 39: 1213-1217, 2002.
45. Oberg BP, McMenamin E, Lucas FL y cols.: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 65: 1009-1016, 2004.
46. Navarro J, Mora C, Muros M, García-Idoate G: Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis. Nephron Clin Pract 95(4): 128-35, 2003.
47. Danesh J, Collins R, Appleby P, Peto R: Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA 279: 1477-1482, 1998.
48. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T y cols.: Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 45: 39-47, 2005.
49. Enia G, Panuccio V, Mallamaci F, Tripepi G, Mandalari A, Zoccali C: Fibrinogen and calcium-phosphate product are predictors of cardiovascular events in the CAPD population. J Nephrol 18: 764-769, 2005.
50. Zoccali C, Mallamaci F, Tripepi G y cols.: Fibrinogen, mortality and incident cardiovascular complications in endstage renal failure. J Intern Med 254: 132-139, 2003.
51. Koch M, Kutkuhn B, Grabensee B, Ritz E: Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: A prospective study in 412 subjects. Nephrol Dial Transplant 12: 2603-2611, 1997.
52. Panichi V, Migliori M, De Pietro S: C-Reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron 91: 594-600, 2002.
53. Pecoits-Filho R, Heimburger O, Barany P y cols.: Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 41: 1212-1218, 2003.
54. Kato A, Odamaki M, Takita T, Maruyama Y, Kumagai H, Hishida A: Association between interleukin-6 and carotid atherosclerosis in hemodialysis patients. Kidney Int 61: 1143-1152, 2002.
55. Shlipak MG, Fried LF, Cushman M y cols.: Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors. JAMA 293: 1737-1745, 2005.
56. Kimmel PL, Phillips TM, Simmens SJ y cols.: Immunologic function and survival in hemodialysis patients. Kidney Int 54: 236-244, 1998.
57. Bologa RM, Levine DM, Parker TS y cols.: Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32: 107-114, 1998.
58. Panichi V, Maggiore U, Taccola D y cols.: Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant 19: 1154-1160, 2004.
59. Rao M, Guo D, Perianayagam MC y cols.: Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 45: 324-333, 2005.
60. Honda H, Qureshi AR, Heimburger O y cols.: Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 47: 139-148, 2006.
61. Van der Sande FM, Coman JP, Leunissen KM: The predictive value of C-reactive protein in end-stage renal disease: is it clinically significant? Blood Purif 24: 335-341, 2006.
62. Caravaca, F, Martín MV, Barroso S, Ruiz B, Hernández-Gallego R: Do inflammatory markers add predictive information of death beyond that provided by age and comorbidity in chronic renal failure patients? Nephrol Dial Transplant 21: 1575-1581, 2006.
63. Pickup J, Crook M: Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41: 1241-1248, 1998.
64. Crook M: Type 2 diabetes mellitus: a disease of the innate immune system? An update. Diabet Med 21: 203-207, 2004.
65. Pickup J: Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27: 813-823, 2004.
66. Satoh J, Yagihashi S, Toyota T: The possible role of tumor necrosis factor-alpha in diabetic polyneuropathy. Exp Diabesity Res 4: 65-71, 2003.
67. Skundric DS, Lisak RP: Role of neuropoietic cytokines in development and progression of diabetic polyneuropathy: From glucose metabolism to neurodegeneration. Exp Diabesity Res 4: 303-312, 2003.
68. Joussen AM, Poulaki V, Mitsiades N y cols.: Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-a suppression. FASEB J (January 30, 2002) 10.1096/fj.01-070fje.
69. Joussen AM, Poulaki V, Le ML y cols.: A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18: 1450-1452.
70. Navarro JF, Mora C: Role of inflammation on diabetic complications. Nephrol Dial Transplant 20: 2601-2604, 2005.
71. Mora C, Navarro JF: Inflammation and diabetic nephropathy. Curr Diab Rep 6: 463-468, 2006.
72. Tashiro K, Koyanagi I, Saitoh A y cols.: Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal 16: 1-4, 2002.
73. Chiarelli F, Cipollone F, Mohn A y cols.: Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes. Diabetes Care 25: 1829-1834, 2002.
74. Morii T, Fujita H, Narita T y cols.: Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J Diabetic Complications 17: 11-15, 2003.
75. Takebayashi K, Matsumoto S, Aso Y, Inukai T: Association between circulating monocyte chemoattractant protein-1and urinary albumin excretion in nonobese type 2 diabetic patients. J Diabetes Complications 20: 98-104, 2006.
76. Chow F, Nikolic-Paterson DJ, Ozols E y cols.: Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 69: 73-80, 2006.
77. Han SY, Kim CH, Kim HS y cols.: Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 17: 1362-1372, 2006.
78. Takebayashi K, Matsumoto S, Aso Y, Inukai T: Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrin Metab 91: 2214-2217, 2006.
79. Matsui H, Suzuki M, Tsukuda R y cols.: Expression of ICAM-1 on glomeruli is associated with progression of diabetic nephropathy in a genetically obese diabetic rat, Wistar fatty. Diabetes Res Clin Pract 32: 1-9, 1996.
80. Coimbra TM, Janssen U, Grone HJ y cols.: Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 57: 167-182, 2000.
81. Chow FY, Nikolic-Paterson DJ, Ozols E y cols.: Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol 16: 1711-1722, 2005.
82. Okada S, Shikata K, Matsuda M y cols.: Intercellular adhesion molecule-1 deficient mice are resistant against renal injury after induction of diabetes. Diabetes 52: 2586-2593, 2003.
83. Hasegawa G, Nakano K, Kondo M: Role of TNF and IL-1 in the development of diabetic nephropathy. Nefrologia 15: 1-4, 1995.
84. Nakamura T, Fukui M, Ebihara I y cols.: mRNA expression of growth factors in glomeruli of diabetic rats. Diabetes 42: 450-456, 1993.
85. Sugimoto H, Shikata K, Wada J, Horiuchi S, Makino H: Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-a and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia 42: 878-886, 1999.
86. Navarro J, Milena F, Mora C y cols.: Tumor necrosis factor-_ gene expression in diabetic nephropathy: Relatioship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int 68(Supl. 99): S98-S102, 2005
87. Navarro J, Milena F, Mora C, León C, García J: Renal proinflammatory cytokine gene expression in diabetic nephropathy. Effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol 26: 562-570, 2006.
88. Navarro JF, Mora C, Rivero A y cols.: Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: Effects of pentoxifylline administration. Am J Kidney Dis 33: 458-463, 1999.
89. Navarro JF, Mora C, Macía M, García J: Inflammatory parameters are independently associated with urinary albumin excretion in type 2 diabetes mellitus. Am J Kidney Dis 42: 53-61, 2003.
90. Navarro JF, Mora C, Muros M, García J: Urinary tumor necrosis factor-a excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrol Dial Transplant 21: 3428-3434, 2006.
91. Hriby Z, Shirota K, Jothy S, Lowry R. Antiserum against tumor necrosis factor-alpha and a protease inhibitor reduce immune glomerular injury. Kidney Int 40: 43-51, 1991.
92. Pan C, Bresnahan B, Albrightson C, Griswold D, Lianos E. Cytokine inhibition preserves renal hemodynamic function following mesangial cell immune injury. J Invest Med 44: 375-381, 1996.
93. Karkar AM, Koshino Y, Cashman S, Dash A, Bonnefoy J, Meager A y cols. Passive immunization against tumour necrosis factor-alpha (TNF-alpha) and IL-1 beta protects from OPS enhancing glomerular injury in nephrotoxic nephritis in rats. Clin Exp Immunol 90: 312-318, 1992.
94. Karkar AM, Smith J, Pusey CD. Prevention and treatment of experimental crescentic glomerulonephritis by blocking tu-mour necrosis factor-a. Nephrol Dial Transplant 16: 518-524, 2001.
95. Segal R, Dayan M, Zinger H, Mozes E. Supression of experimental systemic lupus erythematous (SLE) in mice via TNF inhibition by an anti-TNFa monoclonal antibody and by pentoxifillyne. Lupus 10: 23-31, 2001.
96. Chen YM, Ng YY, Lin SL, Chiang WC, Lan HY, Tsai TJ. Pentoxifylline suppresses renal tumour necrosis factor-a and ameliorates experimental crescentic glomerulonephritis in rats. Nephrol Dial Transplant 19: 1106-1115, 2004.
97. Chen YM, Chien CT, Hu-Tsai MI, Wu KD, Tsai CC, Wu MS y cols. Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney Int 56: 932-943, 1999.
98. Gunduz Z, Canoz O, Per H, Dusunsel R, Poyrazoglu H, Tez C y cols.: The effects of pentoxifylline on diabetic renal changes in streptozotocin-induced diabetes mellitus. Renal Fail 26: 597-605, 2004.
99. DiPetrillo K, Gesek FA. Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am J Nephrol 24: 352-329, 2004.
100. Solerte SB, Fioravanti M, Bozzetti A, Schifine N, Patti AL, Fedele P y cols.: Pentoxifylline, albumin excretion rate and proteinuria in type I and type II diabetic patients with microproteinuria, results of a short-term randomized study. Acta Diabetol Lat 23: 171-177, 1986.
101. Solerte SB, Fioravanti M, Patti AL, Schifino N, Zanoletti MG, Inglese V y cols.: Pentoxifylline, total urinary protein excretion rate and arterial blood pressure in long-term insulin-dependent diabetic patients with overt nephropathy. Acta Diabetol Lat 24: 229-239, 1987.
102. Guerrero-Romero F, Rodríguez-Morán M, Paniagua-Sierra J, García-Bulnes G, Salas-Ramírez M, Amato D. Pentoxifylline reduces proteinuria in insulin-dependent and non-dependent diabetic patients. Clin Nephrol 43: 116-121, 1995.
103. Navarro J, Mora C, Muros M, Macía M, García J. Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a shortterm, prospective, randomised study. Am J Kidney Dis 42: 264-270, 2003.
104. Harmankaya O, Seber S, Yilmaz M. Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. Ren Fail 25: 465-470, 2003.
105. Navarro JF, Mora C, Muros M, García J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomised, controlled trial. J Am Soc Nephrol 16: 2119-2126, 2005.